NEXTERONE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Nexterone, and when can generic versions of Nexterone launch?
Nexterone is a drug marketed by Baxter Hlthcare and is included in one NDA. There is one patent protecting this drug.
This drug has twenty-nine patent family members in thirteen countries.
The generic ingredient in NEXTERONE is amiodarone hydrochloride. There are fifteen drug master file entries for this compound. Thirty-one suppliers are listed for this compound. Additional details are available on the amiodarone hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Nexterone
A generic version of NEXTERONE was approved as amiodarone hydrochloride by TEVA PHARMS on November 30th, 1998.
Summary for NEXTERONE
International Patents: | 29 |
US Patents: | 1 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 2 |
Raw Ingredient (Bulk) Api Vendors: | 111 |
Clinical Trials: | 4 |
Patent Applications: | 793 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for NEXTERONE |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for NEXTERONE |
What excipients (inactive ingredients) are in NEXTERONE? | NEXTERONE excipients list |
DailyMed Link: | NEXTERONE at DailyMed |
Recent Clinical Trials for NEXTERONE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
OHSU Knight Cancer Institute | Phase 2 |
University of Calgary | Phase 4 |
National Institute on Drug Abuse (NIDA) | Phase 4 |
Pharmacology for NEXTERONE
Anatomical Therapeutic Chemical (ATC) Classes for NEXTERONE
US Patents and Regulatory Information for NEXTERONE
NEXTERONE is protected by one US patents.
Patents protecting NEXTERONE
Sulfoalkyl ether cyclodextrin compositions
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Baxter Hlthcare | NEXTERONE | amiodarone hydrochloride | INJECTABLE;INJECTION | 022325-001 | Dec 24, 2008 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Baxter Hlthcare | NEXTERONE | amiodarone hydrochloride | INJECTABLE;INJECTION | 022325-002 | Nov 16, 2010 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Baxter Hlthcare | NEXTERONE | amiodarone hydrochloride | INJECTABLE;INJECTION | 022325-003 | Nov 16, 2010 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for NEXTERONE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Baxter Hlthcare | NEXTERONE | amiodarone hydrochloride | INJECTABLE;INJECTION | 022325-001 | Dec 24, 2008 | ⤷ Sign Up | ⤷ Sign Up |
Baxter Hlthcare | NEXTERONE | amiodarone hydrochloride | INJECTABLE;INJECTION | 022325-001 | Dec 24, 2008 | ⤷ Sign Up | ⤷ Sign Up |
Baxter Hlthcare | NEXTERONE | amiodarone hydrochloride | INJECTABLE;INJECTION | 022325-001 | Dec 24, 2008 | ⤷ Sign Up | ⤷ Sign Up |
Baxter Hlthcare | NEXTERONE | amiodarone hydrochloride | INJECTABLE;INJECTION | 022325-003 | Nov 16, 2010 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for NEXTERONE
See the table below for patents covering NEXTERONE around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Japan | 4923144 | ⤷ Sign Up | |
South Korea | 101314803 | ⤷ Sign Up | |
Australia | 7236491 | ⤷ Sign Up | |
Japan | 2012072160 | SULFOALKYL ETHER CYCLODEXTRIN COMPOSITION | ⤷ Sign Up |
>Country | >Patent Number | >Title | >Estimated Expiration |